BFK — Pharmesis International Share Price
0.000.00%
Last trade - 00:00- SG$19.18m
- SG$21.27m
- CNY67.65m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.73 | ||
| Price to Tang. Book | 1.77 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.58 | ||
| EV to EBITDA | 10.71 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.67% | ||
| Return on Equity | 14.7% | ||
| Operating Margin | 13.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 47.11 | 52.77 | 50.37 | 45.64 | 67.65 | n/a | n/a | 12.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmesis International Ltd. is a Singapore-based investment holding company. The principal activities of the Company and its subsidiaries are development, manufacture, packaging and sale of western medicine, traditional Chinese medicine (TCM), health tonic products, wholesale of drugs, raw products, antibiotics and antibiotic agents. Its pharmaceutical products are sold in the People’s Republic of China (PRC). The Company’s segments include Western drugs, TCM formulated drugs, and Distribution. The Western drugs segment refers mainly to chemically formulated drugs marketed under the Kinna brand. The TCM formulated drugs segment refers to traditional Chinese medicine marketed under the Longlife brand. Distribution segment refers to agency products and internally manufactured products which are marketed through the distribution arm. Its subsidiaries include Chengdu Kinna Pharmaceutical Co., Ltd and Sichuan Longlife Pharmaceutical Co., Ltd.
Directors
- Xuedan Wu CEO (55)
- Jie Qi COO (51)
- Chan Hoe Liang CTR (39)
- Lai Yin Chan SEC
- Pay Lee Lee SEC
- Heng Ching Chew LED (69)
- Chia-Jung Chung NED (28)
- Kwok Kee Chay NID (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 29th, 2003
- Public Since
- October 6th, 2004
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Singapore Exchange Securities Trading Ltd
- Shares in Issue
- 31,700,000
- Address
- 5 Kallang Sector #03-02,, CHENGDU, 349279
- Web
- https://www.pharmesis.com/
- Phone
- +65 68460766
- Auditors
- Ernst & Young LLP
Upcoming Events for BFK
Similar to BFK
Haw Par
Singapore Exchange Securities Trading Ltd
Hyphens Pharma International
Singapore Exchange Securities Trading Ltd
IX Biopharma
Singapore Exchange Securities Trading Ltd
Suntar Eco-City
Singapore Exchange Securities Trading Ltd
FAQ
What is the Pharmesis International share price?
As of Today at 22:37 UTC, shares in Pharmesis International are trading at SG$0.61. This share price information is delayed by 15 minutes.
How has the Pharmesis International share price performed this year?
Shares in Pharmesis International last closed at SG$0.61 and the price had moved by +656.25% over the past 365 days. In terms of relative price strength the Pharmesis International share price has outperformed the FTSE Developed Asia Pacific Index by +677.75% over the past year.
What are the analyst and broker recommendations for Pharmesis International?
There is no consensus recommendation for this security.
Find out moreWhat is the Pharmesis International dividend yield?
Pharmesis International does not currently pay a dividend.
Does Pharmesis International pay a dividend?
Pharmesis International does not currently pay a dividend.
When does Pharmesis International next pay dividends?
Pharmesis International does not currently pay a dividend.
How do I buy Pharmesis International shares?
To buy shares in Pharmesis International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pharmesis International?
As of the previous close price of SG$0.61, shares in Pharmesis International had a market capitalisation of SG$19.18m.
Where are Pharmesis International shares listed?
Here are the trading details for Pharmesis International:
- Country of listing: Singapore
- Exchange: SES
- Ticker Symbol: BFK
What kind of share is Pharmesis International?
Based on an overall assessment of its quality, value and momentum Pharmesis International is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pharmesis International share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Pharmesis International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmesis International. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +74.77%.
As of the last closing price of SG$0.61, shares in Pharmesis International were trading +108.13% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pharmesis International PE Ratio?
The Pharmesis International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SG$0.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pharmesis International?
Pharmesis International's management team is headed by:
- Xuedan Wu - CEO
- Jie Qi - COO
- Chan Hoe Liang - CTR
- Lai Yin Chan - SEC
- Pay Lee Lee - SEC
- Heng Ching Chew - LED
- Chia-Jung Chung - NED
- Kwok Kee Chay - NID